Novartis AG ADR (NVS)vsWW International, Inc. Common Stock (WW)
NVS
Novartis AG ADR
$148.38
-0.96%
HEALTHCARE · Cap: $273.77B
WW
WW International, Inc. Common Stock
$16.25
-5.88%
HEALTHCARE · Cap: $185.48M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 8072% more annual revenue ($56.58B vs $692.33M). WW leads profitability with a 155.5% profit margin vs 23.9%. NVS appears more attractively valued with a PEG of 3.93. WW earns a higher WallStSmart Score of 58/100 (C).
NVS
Hold49
out of 100
Grade: D+
WW
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for WW.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 405 in profit
Keeps 156 of every $100 in revenue as profit
Earnings expanding 5268.0% YoY
Safe zone — low bankruptcy risk
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Smaller company, higher risk/reward
Elevated debt levels
Expensive relative to growth rate
Revenue declined 9.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : WW
The strongest argument for WW centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 155.5% and operating margin at -16.9%.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : WW
The primary concerns for WW are Market Cap, Debt/Equity, PEG Ratio. Debt-to-equity of 1.76 is elevated, increasing financial risk.
Key Dynamics to Monitor
WW carries more volatility with a beta of 1.06 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
WW scores higher overall (58/100 vs 49/100), backed by strong 155.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →WW International, Inc. Common Stock
HEALTHCARE · MEDICAL CARE FACILITIES · USA
WW International, Inc. offers worldwide weight management products and services. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?